Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A FAILED pancreatic cancer treatment could be resurrected as a personalised medicine aimed at one in five patients with the disease, research suggests.
Previous trials showed that the drug rapamycin was ineffective as a general therapy for pancreatic cancer.
But new evidence suggests it might work against a particular type of tumour caused by a fault in the PTEN gene, which influences cell growth.
When rapamycin was given to mice with PTEN-defective pancreatic tumours it stopped cancer cells from spreading. In some cases, the drug also caused tumours to shrink.
http://www.heraldscotland.com/news/health/drug-trials-renewed-hope-for-pancreatic-cancer.24935925
Previous trials showed that the drug rapamycin was ineffective as a general therapy for pancreatic cancer.
But new evidence suggests it might work against a particular type of tumour caused by a fault in the PTEN gene, which influences cell growth.
When rapamycin was given to mice with PTEN-defective pancreatic tumours it stopped cancer cells from spreading. In some cases, the drug also caused tumours to shrink.
http://www.heraldscotland.com/news/health/drug-trials-renewed-hope-for-pancreatic-cancer.24935925